GLP-1, GIP, and Glucagon: The Evolution of Metabolic Agonists

### Gen 1: Semaglutide (GLP-1) The research landscape shifted with the introduction of Semaglutide, a selective GLP-1 receptor agonist. It demonstrated that mimicking incretin hormones could potently regulate insulin secretion and appetite pathways in the brain. ### Gen 2: Tirzepatide (GLP-1 + GIP) Why target one receptor when you can target two? Tirzepatide introduced the concept of **dual-agonism**. By engaging both GLP-1 and GIP receptors, research models showed amplified effects on glucose homeostasis and lipolysis, surpassing single-agonist results. ### Gen 3: Retatrutide (GLP-1 + GIP + Glucagon) The "Triple G." Retatrutide adds Glucagon receptor agonism to the mix. In theory, this third mechanism increases energy expenditure (burning calories) alongside the appetite suppression and insulin regulation of its predecessors. Early research data suggests this could be the most potent metabolic modulator to date. *Explore our full range of metabolic research peptides at peptide limited.*